Voyager Therapeutics Shares Outstanding 2014-2021 | VYGR

Voyager Therapeutics shares outstanding from 2014 to 2021. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Voyager Therapeutics Annual Shares Outstanding
(Millions of Shares)
2020 37
2019 36
2018 32
2017 27
2016 25
2015 4
2014 1
2013 0
Voyager Therapeutics Quarterly Shares Outstanding
(Millions of Shares)
2021-06-30 38
2021-03-31 38
2020-12-31 37
2020-09-30 38
2020-06-30 37
2020-03-31 37
2019-12-31 36
2019-09-30 37
2019-06-30 38
2019-03-31 33
2018-12-31 32
2018-09-30 32
2018-06-30 32
2018-03-31 32
2017-12-31 27
2017-09-30 26
2017-06-30 26
2017-03-31 26
2016-12-31 25
2016-09-30 25
2016-06-30 25
2016-03-31 25
2015-12-31 4
2015-09-30 1
2015-06-30 1
2015-03-31 1
2014-12-31 1
2014-09-30 1
2014-06-30 1
2014-03-31 0
2013-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.112B $0.171B
Voyager Therapeutics, Inc. is a gene therapy company. It focuses on the development of treatments for patients suffering from severe diseases of the central nervous system. Its pipeline includes VY-AADC01, which is in Phase 1b clinical trials for treatment of Parkinson's disease and preclinical programs comprise VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis, VY-FXN01 for Friedreich ataxia and VY-HTT01 for Huntington's disease as well as VY-SMN101 for neuromuscular disease. Voyager Therapeutics, Inc. is headquartered in Cambridge, Massachusetts.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $133.838B 8.91
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.341B 20.90
Biohaven Pharmaceutical Holding (BHVN) United States $8.723B 0.00
Emergent Biosolutions (EBS) United States $2.813B 6.79
Arcus Biosciences (RCUS) United States $2.568B 0.00
Myovant Sciences (MYOV) United Kingdom $2.170B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.949B 0.00
Zymeworks (ZYME) Canada $1.323B 0.00
Ambrx Biopharma (AMAM) United States $0.509B 0.00
SQZ Biotechnologies (SQZ) United States $0.428B 0.00
Enzo Biochem (ENZ) United States $0.174B 51.29